ETON Eton Pharmaceuticals Inc

$ETON · $AQST 🤝 Eton Pharmaceuticals, Inc. entered a license agreement with Aquestive Therapeutics, Inc. to acquire exclusive U.S. commercialization rights to LIBERVANT (diazepam) buccal film, a tentatively FDA-approved treatment for seizure clusters in epilepsy patients. Actionable market event

$ETON Follow-up: Rare-disease drugmaker Eton Pharmaceuticals paid Aquestive $10.0M upfront for U.S. rights to LIBERVANT seizure-rescue film, announced Oct 14, and owes up to $47.5M in milestones plus a mid-teens royalty on net sales. That upfront is ~37% of the $26.8M cash held June 30, though H1 2026 operating cash flow was $14.7M. Aquestive is sole supplier for 20 years. Launch is eyed April 2027, subject to final FDA approval: LIBERVANT is tentatively approved, expected to qualify for full ages 12+ approval as VALTOCO's exclusivity ends Jan 10, 2027.

$ETON (rare-disease drugmaker) licensed U.S. rights to Aquestive's LIBERVANT seizure-rescue film without disclosing upfront, milestone or royalty terms. Eton sizes that U.S. market above $450M a year; it guides 2026 revenue above $145M, held $26.8M cash at June 30 and was worth ~$1.58B at the Oct 12 close. Aquestive supplies the film and may collect royalties on sales. The drug is only tentatively approved: full approval for ages 12+ awaits VALTOCO's exclusivity ending Jan 10, 2027, with launch eyed for April 2027.